MIRA
INFORM REPORT
|
Report Date : |
31.03.2008 |
IDENTIFICATION
DETAILS
|
Name : |
NOBELPHARMA CO LTD |
|
|
|
|
Registered Office : |
Kyodo Bldg (Horidome), 12-10 Nihombashi-Kobunacho Chuoku Tokyo
103-0024 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31/12/2007 |
|
|
|
|
Date of Incorporation : |
Jun 2003 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
R & D of pharmaceuticals |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Maximum Credit Limit : |
Yen 14.1 Million |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Regular |
name
NOBELPHARMA CO LTD
REGD NAME
Nobelpharma KK
MAIN OFFICE
Kyodo Bldg (Horidome), 12-10 Nihombashi-Kobunacho Chuoku Tokyo 103-0024,
JAPAN
Tel: 03-5651-1160
Fax: 03-5651-1222
URL: http://www.nobelpharma.co.jp/
E-Mail address: info@nobelpharma.co.jp
ACTIVITIES
R&D of pharmaceuticals
BRANCHES
Nil
FACTORY(IES)
Partnership factories
OFFICER(S)
JIN SHIOMURA, PRES & CEO
Toshihide Endo, mgn dir & COO
Yen Amount
In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 714 M
PAYMENTS REGULAR CAPITAL Yen 11 M
TREND STEADY WORTH Yen 11 M
STARTED 2003 EMPLOYES 46
COMMENT
R&D OF PHARMACEUTICALS. FINANCIAL SITUATION CONSIDERED
FAIR AND GOOD FOR ORDINARY
BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT
YEN 14.1 MILLION, 30 DAYS NORMAL TERMS
HIGHLIGHTS
The subject company was established by Jin Shiomura in order to make most of his experience when he was with Mitsubishi Chemical Corp & Mitsubishi Wellpharma as director. Toshihide Endo was with Mitsubishi Yuka before joining the firm. Specializes in R&D of pharmaceuticals and launching them in international market. Has strong partnership with Inabata & Co Ltd, specialist chemicals trading firm associated with Sumitomo Chemical (See Registration). Funding is made by Inabata & Co.
FINANCIAL INFORMATION
The sales volume for Dec/2006 fiscal term amounted to Yen 714 million, the first business turnover since the inception. The profits were limited to a minimum amount.
For the term that ended Dec 2007 the net profit was projected at Yen 10 million, on a 12% rise in turnover, to Yen 800 million. Licensing fees are said received.
The financial situation is considered FAIR and good for ORDINARY business engagements. Max credit limit is estimated at Yen 14.1 million, on 30 days normal terms.
REGISTRATION
Date Registered: Jun
2003
Legal Status: Limited
Company (Kabushiki Kaisha)
Authorized: 800
shares
Issued: 233
shares
Sum: Yen
11.65 million
Major shareholders (%)
Inabata & Co Ltd*(50),
Hisanaga & Co (50)
No. of shareholders
2
* Specialized chemicals trading house associated with Sumitomo Chemical, founded1918, listed Tokyo, Osaka S/E’s, capital Yen 9,262 million, turnover Yen 466,096 million, operating profit Yen 7,605 million, recurring profit Yen 7,325 million, net profit Yen 4,570 million, total assets Yen 287,808 million, net worth Yen 82,729 million, employees 3,788, pres Katsutaro Inabata
Nothing detrimental is known as to the commercial morality
of executives.
OPERATION
Activities: R&D of pharmaceuticals and market them in
international market (--100%)
Partnership
Jansen Pharmaceuticals KK; Tava
Pharmaceuticals USA Inc.
(Items handled): orphan drugs (pharmaceuticals for the treatment of rare diseases), for acute cerebral infarction, subarachnoid hemorrhage, brain tumor, primary biliary cirrhosis, anti-hypercholesterolemia, anti-thrombosis, anti-platele, anti-hypertension, anti-angina, anti-diabetes, anti-depression, anti-allergy, other.
Clients
[Pharmaceutical mfg] Fuji Pharma
Co Ltd, other
No. of accounts
10
Domestic areas of activities
Nationwide
Suppliers
[Mfrs, wholesalers] Iryou System Kenkyusho, Mitsubishi Chemical
Medience Corp, Alma Inc, other.
Payment record
Regular
Location
Business
area in Tokyo. Office premises at the
caption address are leased and maintained satisfactorily.
Bank References
MUFG (Ohdenmacho)
Tokyo Shinkin Bank (Nihombashi)
Relations: Satisfactory
FINANCES: (In Million Yen)
|
Terms Ending: |
|
31/12/2007 |
31/12/2006 |
31/12/2005 |
31/12/2004 |
|
Annual
Sales |
|
800 |
714 |
0 |
0 |
|
Recur.
Profit |
|
|
|
|
|
|
Net
Profit |
|
10 |
0 |
0 |
0 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
11 |
11 |
11 |
|
Capital,
Paid-Up |
|
|
11 |
11 |
11 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
12.04 |
|
|
-100.00 |
|
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
.. |
.. |
.. |
|
|
N.Profit/Sales |
1.25 |
0.00 |
0.00 |
0.00 |
|
Notes: Financials are only partially disclosed.
Business resulted for the first time for 31/12/2006 fiscal
term since inception.
Forecast (or estimated) figures for the 31/12/2007 fiscal
term.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)